Podcast appearances and mentions of morgan healthcare conference

On the sidelines of this year's J.P. Morgan Healthcare Conference in San Francisco, BioSpace Senior Editor Annalee Armstrong sat down with Mark McKenna, CEO of Mirador Therapeutics, a member of BioSpace's NextGen Class of 2025. Their discussion here focused on the company's two-pronged approach to developing therapies for inflammatory and fibrotic diseases, as well as the importance of operating under stealth at this time for the biotech.This is the second episode in a special series of The Weekly focused on how NextGen companies are navigating the current business environment.

On the sidelines of this year's J.P. Morgan Healthcare Conference in San Francisco, BioSpace Senior Editor Annalee Armstrong sat down with Kevin Marks, CEO of Delphia Therapeutics, a member of BioSpace's ⁠NextGen Class of 2025⁠. Their discussion here focused on the company's novel science of activation lethality, which involves forcing cancer cells to overactivate and thereby overload cell stress pathways, as well as Delphia's relatively smooth path to a $67 million series A raise thanks to contributions from Google Ventures (GV), where Marks was previously employed.This is the second episode in a special series of The Weekly focused on how NextGen companies are navigating the current business environment.Host⁠Annalee Armstrong⁠, Senior Editor, BioSpaceGuest⁠Kevin Marks⁠, President and CEO, Delphia TherapeuticsFor a complete list of NextGen 2025 companies, ⁠click here⁠.

Stakeholders from across the healthcare and biopharmaceutical industry recently convened in San Francisco for the annual J.P. Morgan Healthcare Conference. In this episode of Connected With Latham, Washington, D.C. partners Chris Schott and Jason B. Caron and associate Danny Machado share key takeaways from the conference, including a renewed optimism from the dealmaking world and the healthcare policy outlook under the new Trump administration.   This podcast is provided as a service of Latham & Watkins LLP. Listening to this podcast does not create an attorney client relationship between you and Latham & Watkins LLP, and you should not send confidential information to Latham & Watkins LLP. While we make every effort to assure that the content of this podcast is accurate, comprehensive, and current, we do not warrant or guarantee any of those things and you may not rely on this podcast as a substitute for legal research and/or consulting a qualified attorney. Listening to this podcast is not a substitute for engaging a lawyer to advise on your individual needs. Should you require legal advice on the issues covered in this podcast, please consult a qualified attorney. Under New York's Code of Professional Responsibility, portions of this communication contain attorney advertising. Prior results do not guarantee a similar outcome. Results depend upon a variety of factors unique to each representation. Please direct all inquiries regarding the conduct of Latham and Watkins attorneys under New York's Disciplinary Rules to Latham & Watkins LLP, 1271 Avenue of the Americas, New York, NY 10020, Phone: 1.212.906.1200

On this week's episode, hosts Chris Garabedian, Brad Loncar,Sam Fazeli and Yaron Werber cover a busy news week ahead of the J.P. Morgan Healthcare Conference as well as a preview of what to expect next week at the event. Thegroup highlights some of the mega private deals announced, including three that involved the licensing of China assets. The hosts zoom out with a recap of end-of-year reports, the current state of the market and XBI outlook. On the data front, Jasper reports positive Phase 1/2 data for chronic urticaria, Vir shares data for masked T-cell engagers and Stoke moves into Phase 3 with their antisense oligonucleotide for Dravet syndrome. The group also discusses Novo's deal with Valo Health, Galapagos' interesting move with new spin out company, whether we've reached ‘peak obesity' and much more. This episode aired on January 10, 2025.

On the sidelines of this year's J.P. Morgan Healthcare Conference in San Francisco, BioSpace Senior Editor Annalee Armstrong sat down with Dannielle Appelhans, CEO of COUR, a member of BioSpace's NextGen Class of 2025. Their discussion here, focused on the company's long history leading up to its $105 million in series A funding at the start of 2024 and the possibility of an initial public offering in the future, among other things, represents the first of a special series of The Weekly focused on how NextGen companies are navigating the current business environment. HostAnnalee Armstrong, Senior Editor, BioSpaceGuestDannielle Appelhans, CEO, COURFor a complete list of NextGen 2025 companies, click here. The NextGen Class of 2025 is brought to you by Pliancy.

On this week's episode, hosts Chris Garabedian, Brad Loncar,Sam Fazeli and Yaron Werber cover a busy news week ahead of the J.P. Morgan Healthcare Conference as well as a preview of what to expect next week at the event. Thegroup highlights some of the mega private deals announced, including three that involved the licensing of China assets. The hosts zoom out with a recap of end-of-year reports, the current state of the market and XBI outlook. On the data front, Jasper reports positive Phase 1/2 data for chronic urticaria, Vir shares data for masked T-cell engagers and Stoke moves into Phase 3 with their antisense oligonucleotide for Dravet syndrome. The group also discusses Novo's deal with Valo Health, Galapagos' interesting move with new spin out company, whether we'vereached ‘peak obesity' and much more. This episode aired on January 10, 2025.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Novo Nordisk's drug Wegovy saw a significant increase in sales in 2024, but analysts are still not satisfied and are questioning why the company can't access more patients, especially in the U.S. Despite this success, there is a lack of female leadership in new biotech companies, with only nine out of 102 launches having a woman at the helm. In other news, GlaxoSmithKline is looking to make deals in the cancer, respiratory, and inflammation sectors, while Valerio is facing financial challenges and has had to cut operations. The biotechnology industry is facing a shift towards more data integration and an increase in mergers and acquisitions.Women leaders in biotech are declining as new company founders prioritize CEOs with a proven track record. Out of the 102 most recent company launches or financings, only nine had a woman at the helm. The lack of women in leadership roles in biopharma continues to be a recurring issue. Biopharma companies are investing more in licensing deals to enrich their pipelines with novel therapies, with a focus on combating patent expirations and generics. Despite challenges, such as a shortage of skilled operators, training programs are being emphasized to upskill teams effectively. Some top biopharma licensing deals of 2024 are highlighted, along with updates on various companies' earnings and strategic moves. The Biotech Sisterhood aims to provide fellowship among women leaders in the industry, showcasing a group of women and allies as their authentic selves at events like the J.P. Morgan Healthcare Conference. Additionally, the newsletter includes job listings and opportunities for industry professionals to stay informed and engaged.

During a panel discussion at this year’s Fierce JPM Week—which took place alongside the annual J.P. Morgan Healthcare Conference in San Francisco—industry experts broke down what it takes to pull off a successful biotech IPO in the current market. This week’s episode of The Top Line dives into the discussion, featuring Fierce Biotech’s Gabrielle Masson as moderator, joined by Septerna CEO and co-founder Jeffrey Finer, M.D., Ph.D.; Rapport Therapeutics Chief Financial Officer Troy Ignelzi; Sofinnova Investments General Partner Maha Katabi, Ph.D.; and Morgan Stanley Executive Director Chirag Surti. In their wide-ranging conversation, the industry leaders spoke about the types of biotechs that debuted on the public market in 2024, the keys to success for an effective IPO and what to expect from the market heading into 2025. To learn more about the topics in this episode:   ‘A really rational IPO environment’: What does it takes for a biotech to go public now? 'Own JP Morgan, don't let JP Morgan own you': Biopharma—and Jill Biden—show up for JPM25 Septerna's $288M IPO is another sign of the market warming to biotech investment Third Rock's Rapport reveals upsized $154M IPO This episode is brought to you by Cencora. Learn more at cencora.com/breakthrough.See omnystudio.com/listener for privacy information.

This year’s edition of the annual J.P. Morgan Healthcare Conference has come to a close, with attendees enjoying sunny skies and a heavy police presence throughout the San Francisco-set event. In this week’s episode of The Top Line, Fierce Pharma’s Zoey Becker and Angus Liu join Fierce Biotech’s Darren Incorvaia to break down the biggest news stories out of the conference. From Johnson & Johnson’s blockbuster acquisition of Intra-Cellular Therapies to former First Lady Jill Biden’s appearance at Fierce JPM Week just days before she left the White House, this year’s conference set the stage for what will surely be an eventful 2025. To learn more about the topics in this episode: ‘Own JP Morgan, don't let JP Morgan own you’: Biopharma—and Jill Biden—show up for JPM25 JPM25: Johnson & Johnson makes a splash, buying out Intra-Cellular Therapies for $14.6B JPM25: First Lady Jill Biden committed to improving women's health as White House tenure winds down JPM25: Strategist GSK acquires IDRx for $1B in hopes of bringing GIST patients new standard of care GSK-backed Ouro Medicines launches into T-cell engager space with $120M and a clinical-stage asset This episode is brought to you by Cencora. Learn more at cencora.com/breakthrough.See omnystudio.com/listener for privacy information.

In this episode, Marc Iskowitz, MM+M's editor-at-large, rounds up the five executives he interviewed over the first two days of the 2025 J.P. Morgan Healthcare Conference. Hear a variety of takes on the state of dealmaking, from the CEOs of a blood-testing startup and clinical-stage biotech firm to the CFO of a med-tech company and the CMO of a health benefits firm.Music by Sixième Son Check us out at: mmm-online.com Follow us: YouTube: @MMM-onlineTikTok: @MMMnewsInstagram: @MMMnewsonlineTwitter/X: @MMMnewsLinkedIn: MM+M To read more of the most timely, balanced and original reporting in medical marketing, subscribe here.

This week, we take a look at some of the highlights from the 43rd Annual J.P. Morgan Healthcare Conference, which took place in San Francisco recently.While there weren't necessarily many financial blockbusters, there were plenty of announcements and discussions on everything from artificial intelligence to the rising influence of Chinese companies and research, to the potential ramifications of the incoming Trump administration in the U.S.To help us navigate some of the highlights of the event, we spoke with Orca Bio's co-founder and CEO, Ivan Dimov, and also Parabilis Medicines' chief business officer, Greg Miller.02:01-03:53: About Orca Bio 03:53-05:43: JPM highlights05:43-07:26: Stand-out deals and announcements07:26-09:01: Were any sectors more prominent than others?09:01-12:38: About Parabilis Medicines12:38-13:58: JPM highlights13:58-16:33: Stand-out deals and announcements  16:33-17:53: Were any sectors more prominent than others?17:53-19:17: Was there an optimistic mood?Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter

Donald Trump was sworn in as the 47th president of the United States on Monday, bringing with him a host of healthcare nominees and potential changes to the FDA, M&A and drug pricing. The new administration was a key focus point at the 2025 J.P. Morgan Healthcare Conference last week, where Annalee Armstrong spoke to executives from several companies about what they're expecting from a second Trump term. Also at JPM, Mirador Therapeutics CEO Mark McKenna boldly predicted that 2025 would see the return of the megamerger. Speaking of M&A, Annalee spoke with leaders from Biogen, who declined to address the company's unsolicited takeover bid for Sage Therapeutics. For its part, Sage sued Biogen last week, “seeking preliminary injunctive relief to enforce a standstill agreement.” Meanwhile, Gilead CEO Daniel O'Day addressed the split of Galapagos—a company Gilead has poured more than $5 billion into since 2019. Check out more personal stories from JPM here. In the obesity space, Novo Nordisk reported data from a Phase III trial showing that a high dose of Wegovy elicited more weight loss than the approved regimen—but still fell short of results posted by Eli Lilly's Zepbound. Relatedly, Wegovy and sister drug Ozempic are both on the list of the next fifteen drugs whose prices could be negotiated under the Inflation Reduction Act. Finally, the FDA on Friday made its first high-profile decision of the year, greenlighting AstraZeneca and Daiichi Sankyo's Dato-DXd—now Datroway—to treat certain types of advanced breast cancer. The approval is the first for the highly touted antibody-drug conjugate, which is also under FDA review for EGFR-mutated non-small cell lung cacner. Analysts expect 2025 to be a pivotal year for the ADC.

Sunshine and a stream of deals brightened the mood at this year's J.P. Morgan Healthcare Conference, offering a pleasant counterpoint to continued pessimism over the state of the capital markets. On the latest BioCentury This Week podcast, BioCentury's editors deliver their takeaways from biotech's annual kick-off event from megarounds and Asian newcos to the new state of M&A and pending change at FDA.View full story: https://www.biocentury.com/article/65472300:00 - Introduction01:52 - Market Sentiments and Deal Expectations04:42 - Cross-Border Deals and Asia's Growing Influence07:12 - Neurology and Innovation in Biotech14:44 - VC Trends and Megarounds20:00 - Upcoming East West SingaporeTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

Jeff Jonas (Research Analyst) highlights two exciting acquisitions announced during the J.P. Morgan Healthcare Conference in San Francisco. To learn more about Gabelli Funds' fundamental, research-driven approach to investing, visit https://m.gabelli.com/gtv_cu or email invest@gabelli.com. Connect with Gabelli Funds: • Twitter - https://twitter.com/InvestGabelli • Instagram - https://www.instagram.com/investgabelli/ • Facebook - https://www.facebook.com/InvestGabelli • LinkedIn - https://www.linkedin.com/company/investgabelli/ http://www.Gabelli.com Invest with Us 1-800-GABELLI (800-422-3554)

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma & Biotech world.The J.P. Morgan Healthcare Conference saw a surge in biopharma deals, with companies like Eli Lilly, GSK, and Gilead announcing billion-dollar deals. Pfizer and Kailera Therapeutics presented updates on obesity treatments, while Biogen and Eisai are seeking FDA approval for new formulations of an anti-amyloid antibody. Other news includes Regeneron's success in a phase III skin cancer trial and Lilly's acquisition of a new molecule. The industry sentiment has been boosted by the flurry of deals at the conference.

With the 2025 J.P. Morgan Healthcare Conference underway, MM+M's Editor-at-Large Marc Iskowitz provides an on-the-ground update from San Francisco. Additionally, Managing Editor Jack O'Brien, Senior Pharma Reporter Lecia Bushak and Reporter Heerea Rikhraj discuss Publicis Health Media President Andrea Palmer's takeaways from the 2025 Consumer Electronics Show as well as Haleon's Dry January event in the West Village.Music by Sixième Son Check us out at: mmm-online.com Follow us: YouTube: @MMM-onlineTikTok: @MMMnewsInstagram: @MMMnewsonlineTwitter/X: @MMMnewsLinkedIn: MM+M To read more of the most timely, balanced and original reporting in medical marketing, subscribe here.

The J.P. Morgan Healthcare Conference kicked off Monday with a flood of high-value deals, reinvigorating sentiment across the biopharma industry. Johnson & Johnson made the biggest splash, acquiring neurology leader Intra-Cellular Therapies for $14.6 billion, while GSK picked up precision therapy specialist IDRx for $1B upfront and Eli Lilly laid down up to $2.5 billion for Scorpion's PI3Kα inhibitor program. Meanwhile, the immunology and inflammation space continues to fire on all cylinders as Gilead invests up to $1.7 billion for LEO Pharma's preclinical oral small molecule STAT6 program. And those are only the deals accepted by both parties. Prior to the conference, Biogen offered to acquire its struggling neuro partner Sage Therapeutics for around $469M. The proposal follows a catastrophic run for Sage, which has seen its shares fall more than 90% in the past two years. 2024 sales and earnings forecasts have also generated attention this week, with Sarepta reporting that Duchenne muscular dystrophy gene therapy Elevidys beat analysts' expectations in the fourth quarter, and Eli Lilly projecting a full-year revenue miss driven largely by lower-than-expected sales of GLP-1 blockbusters Zepbound and Mounjaro. As expected, obesity has been a hot topic at JPM, with Pfizer CEO Albert Bourla announcing that his company is going “all in” in the space. This follows new FDA guidance revealed last week recommending a minimum weight loss threshold for drug developers. Among the many companies taking notice is newcomer Verdiva Bio, which launched last week with more than $410 million in opening funds. Also debuting last week was Kardigan, which raised $300 million to tackle heart disease. Kadigan joins a resurgent cardiovascular space, where several companies—including those developing gene therapies—are targeting myriad diseases. Finally, BioSpace senior editor Annalee Armstrong caught up with Daphne Zohar, CEO of BioSpace NextGen 2025 company Seaport Therapeutics Daphne Zohar, who offered her thoughts on the current state of the neuropsychiatric space.

Carl Quintanilla, Jim Cramer and David Faber led off the show with market reaction to wholesale inflation data: The December Producer Price Index came in cooler than economists' forecasts. The anchors also discussed China reportedly weighing a sale of TikTok's U.S. operations to Elon Musk. At the J.P. Morgan Healthcare Conference in San Francisco, Jim interviewed Eli Lilly CEO David Ricks about the company's latest guidance and road ahead for its weight loss drugs. Also in focus: "Magnificent 7" movers, KB Home beats, Signet Jewelers plunges, the California wildfires effect.  Squawk on the Street Disclaimer

Carl Quintanilla, Jim Cramer and David Faber explored what to make of tech sector weakness following Friday's sell-off. The anchors also reacted to comments Mark Zuckerberg  made on Joe Rogan's podcast. The Meta CEO slammed Apple and weighed in on "masculine energy." At the J.P. Morgan Healthcare Conference in San Francisco, Jim discussed his CEO lineup for Monday's night's "Mad Money" as well as the challenges facing the health care sector. Also in focus: Johnson and Johnson to acquire drugmaker Intra-Cellular Therapies for $14.6 billion, Moderna plunges on weak 2025 sales guidance, California wildfires impact, sources tell David that Cleveland-Cliffs is partnering with Nucor in a potential bid for U.S. Steel.Squawk on the Street Disclaimer   

J&J's $14.6 billion takeout of neurology play Intra-cellular Therapies headlined a buzzy start to the J.P. Morgan Healthcare Conference, where a flurry of deal announcements recalled the conference's pre-pandemic days. On the latest BioCentury This Week podcast, BioCentury's editors discuss the takeout of Intra-cellular, the third 11-digit neuro M&A in the past 13 months, as well as M&A involving Idrx and GSK, and Scorpion Therapeutics and Eli Lilly. Turning to Washington, the team explores what's behind BIO CEO John Crowley's visit to Mar-a-Lago to meet with President-elect Donald Trump, impending changes at FDA under Trump 2.0 and key takeaways from Rep. Jake Auchincloss appearance on BCTW's sister podcast, The BioCentury Show. The team also breaks down the key trends in the past year in FDA approvals. This episode of BioCentury This Week was sponsored by ICON Biotech.View full story: https://www.biocentury.com/article/65469400:01 - Sponsor Message: ICON Biotech02:38 - JPM Deal Buzz11:20 - Washington Update16:08 - Rep. Auchincloss' Take on Biopharma 21:01 - FDA Regulatory DecisionsTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Galapagos is set to split into two entities by mid-2025, creating a new innovative medicines specialist and a cell therapy company. Novo has invested $4.6 billion to expand its deal with Valo, aiming to maintain leadership in the cardiometabolic space. Tenvie, supported by venture partners, will be focusing on developing brain-penetrant small molecules for neurological and metabolic diseases.The trend of licensing deals in the pharmaceutical industry is on the rise, with experts debating whether it is a sign of desperation or a crucial part of the biotech ecosystem. Roche is in the final stages of acquiring Poseida for up to $1.5 billion, while Cassava has had to lay off a third of its staff following a setback in an Alzheimer's drug trial. Major pharmaceutical companies are looking towards China for potential deal opportunities, despite regulatory uncertainty in the region. The FDA is considering setting a bar for weight-loss therapies as the obesity space continues to heat up. Looking ahead to 2025, there is a cautiously optimistic outlook for the biopharma industry, with predictions of increased M&A activity leading up to key events like the J.P. Morgan Healthcare Conference and important FDA decisions.As licensing deals become more common in the biotech industry, big pharma companies are exploring partnerships in China. The industry is gearing up for the J.P. Morgan Healthcare Conference with a sense of uncertainty after M&A activity did not meet expectations in 2024. Biospace's NextGen Class of 2025 features startups focusing on emerging trends in biopharma, attracting investments from major players.Companies like Roche, Merck, and Novo are making significant moves in the biopharma space, shaping the industry landscape. Job opportunities are available in various sectors, including positions like Chief of Staff and Senior Director in IT and Translational Neuroscience. Biospace is working on enhancing user experience by personalizing emails based on individual preferences.Thank you for tuning in to Pharma and Biotech Daily, where we bring you the latest updates and insights from the world of pharmaceuticals and biotechnology.

Jeff Berg, president of AbelsonTaylor Group, offers an independent's perspective on last year's announced merger of Omnicom with Interpublic Group, in an interview with Jack O'Brien.And on our Trends segment, Marc Iskowitz previews the 43rd annual J.P. Morgan Healthcare Conference, kicking off next week in San Francisco. Tune in, as well, for a big reveal involving the brand's spring conference, MM+M Transform, coming up on April 3, 2025, in New York City.Music by Sixième Son Check us out at: mmm-online.com Follow us: YouTube: @MMM-onlineTikTok: @MMMnewsInstagram: @MMMnewsonlineTwitter/X: @MMMnewsLinkedIn: MM+M To read more of the most timely, balanced and original reporting in medical marketing, subscribe here.

Happy New Year! BioSpace released our NextGen: Class of 2025 this week, highlighting 25 biopharma startups to watch this year. The companies on this list are not afraid of a challenge, wading into some of biopharma's most competitive therapeutic spaces. As analysts predict an uptick in M&A in '25, could some of them be potential targets? One NextGen 2025 company that could already be fielding calls is Metsera, which reported promising Phase II data for its investigational subcutaneous GLP-1 therapy on Tuesday. The GLP-1 space continues to garner significant attention, with both Eli Lilly and Novo Nordisk seeking to protect their drugs against competition from compounders. This strategy makes a lot of sense as the sizzling class continues to expand into heart disease, sleep apnea and metabolic dysfunction-associated steatohepatitis, among other indications. On the regulatory side, the FDA approved 55 novel medicines in 2024—including a few inaugural company approvals—and is looking ahead to several key PDUFA dates in Q1, 2025. Meanwhile, the agency released three new guidance documents seeking to provide clarity around confirmatory trials supporting accelerated approvals, the use of AI in drug development and the use of tissue biopsies in clinical trials. Finally, BioSpace senior editor Annalee Armstrong heads to the J.P. Morgan Healthcare Conference next week as biopharma seeks an M&A spark to improve the currently a gloomy sentiment. Stay with us for all the biggest news coming out of JPM.

Rob Williamson's mind and hands have shaped more than 20 biotech startups, leading some to IPO and landing others firmly in Big Bio through acquisition by companies like Merck. Hanging around as many successful exits as Williamson has seen, one might become expert via osmosis. But Williamson isn't passive about honing his vision for progressive therapeutic dealmaking. He's an active leader, and for this episode of the Business of Biotech, he took a breather from a hectic agenda at the J.P. Morgan Healthcare Conference to share some introspection on the work he's done, the work he's doing at Triumvira with T-cell therapeutics in oncology, the big opportunities in cancer therapeutics, and what's coming next.Subscribe to the #BusinessofBiotech newsletter at bioprocessonline.com/bob for more real, honest, transparent interactions with the leaders of emerging biotech. It's a once-per-month dose of insight and intel that you'll actually look forward to receiving! Check it out at bioprocessonline.com/bob!

Over the last few years, the MedTech market has been navigating an unpredictable environment due to macro-economic factors and pandemic-driven activity. As we start off 2024, there's a prevailing feeling that this market is finally starting to stabilize. In this episode, Jen is joined by Vynamic's Anila Patel and Head of Health Technology Sector, Mary Virzi, to chat about what MedTech moves we've seen so far and what we can expect as 2024 kicks into gear.  Podcast Tags: healthcare, medtech, product launch, medical device, health tech, healthcare technology Source Links: The biggest stories from the 2024 J.P. Morgan Healthcare Conference 5 medtech trends to watch in 2024 MEDTECH AND DIAGNOSTICS MARKET: 2023 TRENDS AND 2024 OUTLOOK Medtronic aims to leverage medical device data for AI-enabled care 4 heart device trends shaping the medtech sector in 2024 J&J's Biosense Webster puts forward pulsed field ablation data showing no afib after one year Boston Scientific nets Farapulse approval, pushes back US TAVR launch J&J's Biosense Webster puts forward pulsed field ablation data showing no afib after one year Medtronic snags first pulsed field ablation approval in US Spotlight – J&J takes on Medtronic and Boston in pulsed field ablation Increasing diabetes awareness boosts the diabetes care devices market Panel – Mary Virzi, Anila Patel, Jen Burke Research & Production – Adrea Cope, Everly Petruzzelli Recording & Editing – Mike Liberto, Rachel Skonecki For additional discussion, please contact us at TrendingHealth.com or share a voicemail at 1-888-VYNAMIC.

In this episode, Jen sits down with Vynamic's Deal Activation & Partnership Enablement Service Leads, Senior Director Kevin Fletcher and Executive Sean Martin, to discuss recent newsworthy items coming out of the J.P. Morgan Healthcare Conference, including the major acquisitions and deals announced, particularly those focused on AI and digital innovation.Check out Vynamic's Deal Activation & Partnership Enablement Service page to learn more about how Vynamic helps clients manage critical, time-sensitive activities across the deal life cycle. Podcast Tags: healthcare, healthcare news, life sciences, pharmaceutical, JP Morgan, deal activation, partnerships, mergers, acquisitions, AI, digital innovation Source Links: Inizio Biotech key takeaways from JPM industry event Cigna sells Medicare business to Health Care Service for $3.3 bln Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics J&J, Merck and Boston Scientific Go on $6.4 Billion Buying Spree Amazon rolls out digital health benefits program, taps Omada Health as launch partner What the Health Care Sector Was Selling at the J.P. Morgan Confab Jefferson Health says LVHN merger would double its insurance business within 2 years Panel – Jen Burke, Kevin Fletcher, Sean Martin Research & Production – Anna Briccetti, Jen Burke Recording & Editing – Mike Liberto, Rachel Skonecki For additional discussion, please contact us at TrendingHealth.com or share a voicemail at 1-888-VYNAMIC.

Rene Thomas Folse, JD, Ph.D. is the host for this edition which reports on the following news stories: WCAB Rejects Psychologist's Psyche Claim Against Dept. of Corrections. S.F. City Attorney Battles U.S. News & World Report Over Hospital Ranking. CEO of Whittier Health Clinic Sentenced to 10 Years for Billing Fraud. Cheesecake Factory Settles SoCal Wage Violations for $1M. Study Shows VA Healthcare More Efficient, Less Costly & Better Results. Technology Industries Dominate 2024 J.P. Morgan Healthcare Conference. Sedgwick Introduces it's Connect 2024 Industry Trends Agenda. NSC Expands Workplace Safety Grant Programs by $260K.

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, to discuss what companies in the healthcare and diagnostics industries are focusing on in 2024.Their discussion includes:Insights from the J.P. Morgan Healthcare Conference, and where investments are happening in the diagnostics industry.Observations from visiting Southeast Asia around international healthcare innovation and testing accessibility. The importance of private-public partnerships and investments to advance global health.

Listen to the latest episode of the Freshfields MedTech podcast as partner Vinita Kailasanath and Managing Director of Ivy Tree Advisors, Jonathan Olsen, discuss key MedTech hot topics coming out of this year's J.P. Morgan Healthcare Conference.

The Driving the Deal podcast is back for its fourth season! We're bringing you the latest topics impacting the healthcare private equity space. In this new episode, Brian Fortune, Senior Managing Director at Farragut Square Group, and Krist Werling, McDermott Partner and co-head of the Firm's Private Equity Practice Group, are joined by Farragut Square Group's Assistant Vice President, Holly Stokes, and Director of Research, Jackie Williams, to provide insights from the 2024 J.P. Morgan Healthcare Conference in San Francisco. Together, they discuss what people are expecting this year in the deal market, providing key takeaways and sharing their thoughts on various sector themes.

Weight loss drugs are taking center spotlight, but other developing treatments could change how we live. Deidre Woollard caught up with Motley Fool biotech analyst Karl Thiel to discuss: - Biogen's next shot at an Alzheimer's treatment. - Why companies can't “muscle their way” into making new molecules. - How NVIDIA could change drug development.  - Moderna's vaccine strategy Companies discussed: LLY, NVO, GPCR, NVDA, DXCM, NVDA, BIIB, GEHC, MRNA, NVCR, VRTX Host: Deidre Woollard Guest: Karl Thiel Producer: Ricky Mulvey Engineer: Tim Sparks Learn more about your ad choices. Visit megaphone.fm/adchoices

As the 42nd J.P. Morgan Healthcare Conference wraps up, host David Rawlings and Mike Gaito, Global Head of Healthcare Investment Banking, explore the recent M&A trends and the impact of economic factors on healthcare investments. Dive into the latest developments from innovation in AI and machine learning to data management and outcomes-driven healthcare services. How can boards and management teams navigate the healthcare sector in 2024?   This episode was recorded on January 12, 2024. This material was prepared by certain personnel of JPMorgan Chase & Co. and its affiliates and subsidiaries worldwide and not the firm's research department. It is for informational purposes only, is not intended as an offer or solicitation for the purchase, sale or tender of any financial instrument and does not constitute a commitment, undertaking, offer or solicitation by any JPMorgan Chase entity to extend or arrange credit or to provide any other products or services to any person or entity. © 2024 JPMorgan Chase & Company. All rights reserved.

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in the Pharma and Biotech world. Today we have a packed episode with news from various sectors of the industry. Let's dive in!## SnapLVV: Overcoming bottlenecks in LVV productionSnapLVV, a new offering powered by Resilience, aims to overcome bottlenecks in the production of lentiviral vector (LVV) for cell therapy. LVV is a critical component in therapy development, but creating the necessary material can take up to two years, causing delays. With SnapLVV, users can secure a batch of LVV with the specific material they need for phase I of their therapy. Resilience offers expert understanding and streamlined processes for LVV manufacturing. To determine if SnapLVV is a good fit, users can connect with Resilience and discuss their vector needs.## Apple's smartwatches redesign and other industry updatesApple is redesigning its smartwatches to avoid a ban on sales due to a patent dispute with Masimo. The new versions will not have a pulse oximetry feature. In other news, Integer has acquired Pulse Technologies for $140 million. Pulse specializes in micro machining components for medical devices. EssilorLuxottica is integrating technology into glasses to target the hearing loss market. ResMed's magnetized masks have been linked to patient injuries, according to the FDA. The UK's MHRA has shared a roadmap for a new regulatory framework for medtech.## Allakos announces restructuring plan and IPO filingsBiotech company Allakos plans to cut its workforce by 50% after the failure of its lead inflammatory candidate in two Phase II studies. The company will focus on other product candidates. In other news, Alto Neuroscience and Kyverna Therapeutics have filed for IPOs, joining the growing number of biotech companies seeking to go public. Orion Group has announced a $415 million investment in Legochem Biosciences, securing a majority stake. Several significant deals were secured during the J.P. Morgan Healthcare Conference.## Insights into the biotech industry and upcoming trendsDespite setbacks, the biopharma industry is cautiously optimistic about a rebound in 2024. Increased dealmaking and a stock market run have boosted the sector. However, fewer biotechs are going public, and investors are focusing on drugs in advanced testing. Women's health companies are seeing growing opportunities, and real-world data is playing a critical role in shaping pharma's strategies. The industry is aware of the challenges and lessons from the past.## Webinar on cfHPV-DNA biomarker for HPV+ OPSCCA webinar will discuss the potential of cfHPV-DNA as a prognostic biomarker for HPV+ OPSCC. It aims to explore how this biomarker can enhance clinical research and drug development. The webinar will cover historical limitations in biomarker testing and provide real-world data behind cfHPV-DNA. It will inform sponsors and CROs on leveraging cfHPV-DNA in drug development.## Summary of biotech industry articles and newsInvestors and executives at the J.P. Morgan conference are optimistic about the sector but stress the need for leaner operations and focus on first medicines. The formation of Arena Bioworks, a new biomedical institute blending academic and venture capital research models, is discussed. AI's impact in biotech is explored through a Q&A with Chris Gibson from Recursion. Other topics from the J.P. Morgan conference include Novartis' head start in radiopharma, Pfizer's challenges, and the building of biotech platforms. The industry has regained some optimism due to recent deals and stock market momentum.And that's all for today's episode! Thank you for tuning in to Pharma and Biotech Daily. Stay informed and have a great day!

Cautious optimism was the theme during a J.P. Morgan Healthcare Conference week that featured patchy skies, large-but-not-mega deals and a surfeit of sideline summits around San Francisco's Union Square. BioCentury's editorial team discusses the week's M&A deals, including J&J's $2 billion takeout of ADC company Ambrx, and Merck & Co. acquiring T cell engager biotech Harpoon for nearly $700 million; takeaways from the Sachs Neuroscience Innovation Forum and other adjacent forums; and investor sentiment heading into the New Year.

Good morning from Pharma and Biotech Daily, the podcast that gives you only what's important to hear in the Pharma and Biotech world. Today, we have a packed episode with news from clinical research, FDA updates, biotech acquisitions, the state of innovation in the pharmaceutical industry, and marketing trends for 2024. Let's dive in!In our first news segment, we discuss how the nature of clinical research and patient recruitment has evolved over the past 40 years. Clinical trials have seen significant advancements in treatments and scientific understanding of diseases, which has led to new challenges in patient recruitment. To navigate these changes effectively, sponsors and researchers must understand the shifting landscape of clinical research. A playbook created by members of the Studioid expert network explores these drivers impacting recruitment strategies. It emphasizes the importance of keeping up with these changes to recruit diverse patient populations while managing costs.In FDA news, vaporized hydrogen peroxide has been recognized as an alternative sterilization method to ethylene oxide (ETO) to strengthen the medical device supply chain. GE Healthcare issued a notice about formaldehyde exposure risks from its ventilators, triggering an FDA alert. Livanova announced plans to close its circulatory support business, which is expected to benefit revenue growth and profitability. Nevro is laying off employees to strengthen its financial position. Intuitive CEO Gary Guthart shared at the J.P. Morgan Healthcare Conference that strong robot placements are offsetting a slowdown in bariatric surgeries.Moving on, NPR reports that blood tests can help diagnose Alzheimer's disease, although accuracy varies. The AP highlights the importance of designating disabled people as a health disparity population. WHO reports that nearly 10,000 people died from COVID-19 last month.In biotech news, BioNTech has acquired two preclinical monoclonal antibodies for undisclosed targets from Wuxi Biologics. Gilead Sciences must face consumer claims over older, lower-quality drugs. A study published in the BMJ reveals strong financial ties between the pharmaceutical industry and physicians serving as panelists and task force members of the DSM-5.The pace of innovation in the pharmaceutical industry remains rapid despite challenges. Significant progress has been made in the treatment of Alzheimer's disease with the approval of new drugs. Industry leaders are optimistic about the state of innovation and clinical trials in 2024. Patient recruitment for Alzheimer's research is seen as a key strategy for advancing treatments in this field.Next, we discuss marketing trends expected to go viral in 2024. Creator-led advertising, social commerce, and artificial intelligence are expected to yield fresh potential in marketing strategies. Pepsi Wild Cherry's campaign targeting aging millennials and Disney's contextual ads tied to mood are highlighted as successful examples. Walmart+ has tapped Andy Cohen to help consumers survive "Quitter's Day" in its latest campaign.Lastly, we cover five major storylines in the pharmaceutical industry. Biogen's CEO shares positive progress on their Alzheimer's drug launch. Eli Lilly has launched an online service for telehealth and home delivery of medications. The J.P. Morgan Healthcare Conference had discussions on radiopharma drugmakers and a surprise FTC challenge. The FDA has authorized Florida to import drugs from Canada, potentially paving the way for other states. Drugmakers are focusing on competing in the obesity market and preparing for oncology's next era while dealing with drug pricing regulations.That wraps up today's episode of Pharma and Biotech Daily. Stay tuned for more important news in the world of Pharma and Biotech.

With the 2024 J.P. Morgan Healthcare Conference underway, MM+M's Marc Iskowitz provides an update from on the ground in San Francisco. Digital Editor Jack O'Brien talks with Insilico Medicine President Michelle Chen about the company's ongoing work to bring generative AI's capabilities to the world of clinical research. Senior Reporter Lecia Bushak talks about the Food and Drug Administration's historic move to give Florida the ability to import medications from Canada at much lower prices than in the U.S.Eli Lilly's LillyDirect website launch marks a direct-to-consumer push for GLP-1 drugs like Zepbound, we dive into Defense Secretary Lloyd Austin's controversial prostate cancer treatment saga and examine the brands and influencers toasting to Dry January. Music by Sixième Son.Follow us: @mmmnewsTo read more of the most timely, balanced and original reporting in medical marketing, subscribe here.

Carl Quintanilla, Jim Cramer and David Faber explored what to make of stocks under pressure the morning afterthe Nasdaq's best one-day performance since November -- and a fresh all-time high for Nvidia.Boeing shares extended Monday's losses on new developments surrounding the grounding of its 737 MAX-9 jets. The anchors discussed what pharma CEOs told Cramer at the J.P. Morgan Healthcare Conference, especially when it comes to the burgeoning obesity drug market. Also in focus: Netflix downgraded, the impact of Samsung's profit missand guidance on mega-tech and the chips, HPE said to be in talks to acquire Juniper Networks, Match Group's date with activism. Squawk on the Street Disclaimer

Carl Quintanilla, Jim Cramer and David Faber discussed Boeing shares dragging the Dow lower, after the Federal Aviation Administration ordered a temporary grounding of 171 of the company's 737 MAX-9 jets. The FAA's call for inspections came after a blowout on an Alaska Airlines flight. Both the  carrier and Spirit AeroSystems saw their shares take a hit on news of the grounding. The "Magnificent 7" in the spotlight: Apple looks to rebound after a 6% drop in the first week of 2024, while Nvidia erases last week's losses. Also in focus: The end of a 9-week win streak for the major averages, what to expect from this week's bank earnings, Cramer previews his CEO interviews from the J.P. Morgan Healthcare Conference in San Francisco. Squawk on the Street Disclaimer

A flurry of large acquisitions to close out 2023 is likely to carry into the New Year as pharmas continue to show appetite for late-stage assets. On the latest BioCentury This Week podcast, BioCentury's editors discuss the latest trends in biotech M&A, potential takeout targets for 2024 and the impact on dealmaking of a more aggressive FTC. They also assess sentiment heading into next week's J.P. Morgan Healthcare Conference, analyze future drivers of innovation in biotech, and preview the year ahead in regulation and public policy.

Lecia Bushak explains how Dr. Peter Rezkalla (aka Dr. Disney) has become the med-ed go-to for eight- and 10-year-olds on TikTok. This week's policy update focuses on the pharma industry's planned price hikes for 2024, amid the government's rollout of Medicare price negotiations. We also preview the 42nd annual J.P. Morgan Healthcare Conference. And the health-focused films shortlisted for this year's Oscars top our Trends segment, along with TikTok's hormone balancing trend.  Music by Sixième Son.Follow us: @mmmnewsTo read more of the most timely, balanced and original reporting in medical marketing, subscribe here.

This week, Deloitte's LSHC and M&A leaders are offering a sneak peek at Deloitte's event offerings concurrent to the J.P. Morgan Healthcare Conference. Learn about the exciting and insightful sessions and networking opportunities—and then register to attend them!

This week, Deloitte's LSHC and M&A leaders are offering a sneak peek at Deloitte's event offerings concurrent to the J.P. Morgan Healthcare Conference. Learn about the exciting and insightful sessions and networking opportunities—and then register to attend them!

On this episode, we dig into what makes truly great marketing: the work must be single-minded, authentic, relevant, forward, everywhere, and of course... bold. Three marketing campaigns give us all the goosebumps—as do some recent announcements from CES and the J.P. Morgan Healthcare Conference

Get Opto's best content every day by subscribing to our FREE Newsletter: www.cmcmarkets.com/en/opto/newsletterToday, we have the pleasure of introducing Arelis Agosto, Senior Healthcare Analyst at Global X. In this episode, we explore the transformative landscape of healthcare, diving into the latest breakthroughs in gene therapy & editing and genomic technology and the sector's increasing need for digitisation. Arelis shares insights from the latest J.P. Morgan Healthcare Conference, highlighting how the rapid pace of innovation drives immense investment potential in this space. She guides us through recent advancements in disease prevention strategies, such as soft therapy and enhanced diagnostics, set to reshape patient care. She also highlights key industry leaders, including Illumina, PacBio, and Nvidia, shedding light on why the latter plays a pivotal role in propelling progress, with healthcare now recognised as the world's foremost data-generating industry. Lastly, Arelis dives into Global X's Genomic & Biotechnology ETF [GNOM], designed to provide exposure to the genomic value chain. Before joining Global X in 2022, Arelis worked as a Senior Healthcare Analyst at Third Bridge, covering US life sciences, diagnostics, biotech, pharmaceutical services, and animal health.Check out our daily newsletter: https://www.cmcmarkets.com/en-gb/opto/newsletter---------Past performance is not a reliable indicator of future results.CMC Markets is an execution-only service provider. The material (whether or not it states any opinions) is for general information purposes only and does not take into account your personal circumstances or objectives. Nothing in this material is (or should be considered to be) financial, investment, or other advice on which reliance should be placed. No opinion given in the material constitutes a recommendation by CMC Markets or the author that any particular investment, security, transaction, or investment strategy is suitable for any specific person.The material has not been prepared in accordance with legal requirements designed to promote the independence of investment research. Although we are not specifically prevented from dealing before providing this material, we do not seek to take advantage of the material prior to its dissemination.CMC Markets does not endorse or offer opinions on the trading strategies used by the author. Their trading strategies do not guarantee any return and CMC Markets shall not be held responsible for any loss that you may incur, either directly or indirectly, arising from any investment based on any information contained herein for any loss that you may incur, either directly or indirectly, arising from any investment based on any information contained herein.

Veradigm Inc. Presents at 41st Annual J.P. Morgan Healthcare Conference, Jan-11-2023 03:45 PM

Today we're looking at the biggest trends in U.S. Healthcare M&A as discussed at the recently held J.P. Morgan Healthcare Conference. “We can expect this to be a big year for M&A for Pharmaceutical and medical device companies,” says our guest Rebecca Wenzel, a senior reporter for Mergermarket. “They are sitting on piles of cash that they're ready to deploy, though one of the differences we'll see is that they're going to be more selective about their roster of assets and assets will be met with more due diligence.” Listen to learn about: The rise of bolt-on deals in Biophrama and medical devices Expected wave of Healthcare IT deals at reset valuations Consolidation in private practice management How financing challenges are affecting deals Dealcast is presented by Mergermarket and SS&C Intralinks.

It's a volatile time for biopharma, and a unique juncture in our industry's history. War in Ukraine, a bearish market and supply chain chaos are just a few of the factors that kept much of the industry away from the table. Entering 2023, the investment and dealmaking panorama remains a puzzle. Despite worries and uncertainties, there are hints that dealmaking intensity may be poised for a rebound after a year of inertia that mirrored the slump in major biotech stock indexes. What lies ahead for dealmaking in the biopharmaceutical industry in 2023?Our 13th Dealmakers' Intentions Survey attempts to answer this question, based on responses from more than 100 members of the biopharma community, most of them with executive-level influence on decision-making. This report, released recently at Biotech Showcase—an event co-located with the famous J.P. Morgan Healthcare Conference in San Francisco—captures their expectations for deal activity, supply and demand for specific assets and different development stages, pitfalls leading to failure and other factors affecting dealmaking. Neel Patel, Executive Managing Director, Commercial Advisory Group at Syneos Health and lead author of the report, joins the podcast to discuss the industry's first time back in person at J.P. Morgan in three years, as well as key findings from the survey.Read the latest Dealmakers' Intentions report here.If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you'll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you're hearing? Be sure to rate and review us! We want to hear from you! If there's a topic you'd like us to cover on a future episode, contact us at podcast@syneoshealth.com. 

Josh and Brian are joined by Aledade's Chief Financial Officer, John Doyle. John provides a brief recap on the recent J.P. Morgan Healthcare Conference, how Aledade's alignment as a company drew him in, and the many factors companies take into consideration before going public.

SPECIAL EDITION: BoB@JPMThe Business of Biotech podcast took to the streets of San Francisco during the 41st Annual J.P. Morgan Healthcare Conference. This week's episode features a conversation with Sangamo Therapeutics CEO Sandy Macrae, Ph.D., who rationalizes the company's aggressive pipeline development and its decision to invest in multinational AAV and cell therapy manufacturing facilities in France and California. Dr. Macrae zeroes in on the relationship between people and processes that's enabled the company to grow to more than 500 associates working on nearly 20 cell therapy, gene therapy, and genome engineering programs. Subscribe to the NEW #BusinessofBiotech newsletter at bioprocessonline.com/bob for more real, honest, transparent interactions with the leaders of emerging biotech. It's a once-per-month dose of insight and intel that you'll actually look forward to receiving! Check it out at bioprocessonline.com/bob!

Hosts Gregg Masters and Fred Goldstein weigh in on select topline takeaways from the 41st JP Morgan Healthcare Conference. In addition to the takeaways, they discuss the current state of population health management and key innovation themes likely to drive the 2023 narrative. To stream our Station live 24/7 visit www.HealthcareNOWRadio.com or ask your Smart Device to “….Play Healthcare NOW Radio.” Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen

William Morice II, M.D., Ph.D., president and CEO of Mayo Clinic Laboratories, joins “Answers From the Lab” for his weekly leadership update with host Bobbi Pritt, M.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic. In this episode, Dr. Morice shares his biggest takeaways from this year's J.P. Morgan Healthcare Conference in San Francisco, California, and gives an update on the COVID-19 public health emergency.

The JP Morgan Healthcare conference is a great place to check the instruments and see how the industry is doing. Today we take a look at what we heard.

We've got new information about Dexcom's G7 launch and much more. CEO Kevin Sayer says it'll be available in the US before the end of March. Sayer joins us from the J.P. Morgan Healthcare Conference in San Francisco. He talks about Dexcom's pump partners, when the FDA will let them put in features they already have in Europe but not here, and answers a lot of your questions. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Stacey mentioned this link during the episode: www.dexcom.com/g6-medicare Check out Stacey's books! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Learn more about OMNIPOD* *Learn more about AFREZZA* *Learn more about DEXCOM*

On a special edition of PopHealth Week, co-hosts Gregg and Fred weigh in on select topline takeways from the 41st JP Morgan Healthcare Conference. In addition to topline takeaways, they discuss current state of population health management and key innovation themes likely to drive the 2023 narrative.   ==##==  

With the 2023 J.P. Morgan Healthcare Conference drawing to a close, we look back on the biggest news of the meeting, what it means for the year in biotech ahead, and whether the industry's biggest annual gathering might finally have outgrown its host city.

Carl Quintanilla, Jim Cramer and David Faber discussed the markets extending gains after a positive first week of 2023 for stocks. The anchors also explored woes for a pair of retailers: Shares of Lululemon and Macy's each down sharply on holiday quarter guidance. Carl, Jim and David reacted to Ant Group founder Jack Ma ceding control of the Chinese fintech giant, and the boost to shares of Alibaba, which owns a roughly 33% stake in Ant. Merck CEO Robert Davis offered his outlook for the pharma giant "First on CNBC" from the J.P. Morgan Healthcare Conference in San Francisco. Also in focus: Goldman Sachs reportedly set to begin layoffs, plus a look at the stocks rising more than 100% on M&A news.

A trio of billion dollar deals for late-stage and commercial assets featuring contingent value rights were among the highlights of the first day of the J.P. Morgan Healthcare Conference in San Francisco on Monday. BioCentury's editors discuss AstraZeneca's takeout of CinCor, Ipsen's buy of Albireo and Chiesi's acquisition of Amryt as well as other takeaways from JPM, the CERSI summit and the Neuroscience Innovation Forum. The team also discusses the latest in Alzheimer's.

The Dow slumped over 300 points and Jim Cramer is digging deeper into today's market moves. Then, Constellation Brands fell 10% today after earnings and Cramer is getting a better read on the quarter with CEO Bill Newlands. Next, Cramer's rounding up the best performing stocks in the Nasdaq last year and sharing names for investors to consider in 2023. Plus, Cramer gets a preview of the annual J.P. Morgan Healthcare Conference with analyst Lisa Gill.

First, we delve into a sweeping congressional investigation into the FDA's approval of the last treatment for Alzheimer's disease and what it means for the next one. We also preview the upcoming J.P. Morgan Healthcare Conference and the biggest biotech events of 2023.

What does it mean to be a values-driven leader? In this episode, David Rawlings, CEO for JPMorgan Chase & Co. in Canada, sits down with Johnson & Johnson's former Chairman and CEO, Alex Gorsky. They discuss how Alex's values-driven leadership has influenced his career, from his military service to his roles as Chairman and CEO of J&J. Ahead of the 41st J.P. Morgan Healthcare Conference, Alex shares how he led J&J by driving innovation especially during the COVID-19 pandemic. Alex also talks about his experiences as a board member and advises CEOs and directors on navigating market uncertainty and advocating for businesses to have a broader impact on society. 00:05 - Intro 02:26 – Growing Up in the Midwest 04:36 – From West Point to the West Coast 07:55 – Becoming a Leader at J&J 11:48 – COVID-19 – A Seminal Career Experience 17:25 – Making Big Strategic Moves 19:42 – Industry Collaboration at J.P. Morgan's Healthcare Conference 21:16 – Healthcare Trends and Insights 25:48 – Advice for CEOs and Board Directors This episode was recorded on December 14, 2022. This material was prepared by certain personnel of JPMorgan Chase & Co. and its affiliates and subsidiaries worldwide and not the firm's research department. It is for informational purposes only, is not intended as an offer or solicitation for the purchase, sale or tender of any financial instrument and does not constitute a commitment, undertaking, offer or solicitation by any JPMorgan Chase entity to extend or arrange credit or to provide any other products or services to any person or entity. © 2023 JPMorgan Chase & Company. All rights reserved.

This episode features Amber Walsh, Partner at McGuireWoods LLP. In this episode, she discusses PE trends she's following after attending the most recent J.P. Morgan Healthcare Conference, business strategy, and more.

Since the beginning of the pandemic, Dan Michelson has held at least three to five zoom calls per day with hospital CFOs across the country. As the industry navigated the most disruptive and uncertain times in modern history, healthcare leaders turned to Dan for his insight and advice because of the unparalleled visibility he has into the market through his company, Strata Decision Technology. Strata provides financial planning and analytics software for more than 400 health systems and 2,000 hospitals – in other words, about half the U.S. healthcare provider market.While health leaders turn to Dan on an ongoing basis, he's also become known for articles every January that analyze the top trends and topics discussed at the annual J.P. Morgan Healthcare Conference. In fact this year, Dan published two articles – one in Fortune and one in STAT News – and for the third year running, joined Keith Figlioli to dive even deeper with a discussion on the Healthcare is Hard podcast.What surprised both Dan and Keith the most at this year's event is the fact that COVID was not really a focus. CEOs and CFOs from some of the nation's most prominent health systems that presented during JPM's non-profit track barely mentioned it because it's now become a normal part of every health system's operating model. COVID is no longer a specific focus because it's an intrinsic element in everything they do, and they're prepared for it.But Dan's articles touched on some of the other major topics from JPM that he and Keith talk about in this episode, including:Staffing. Staffing. Staffing. The headline of Dan's article in STAT News captured the mood best: “Covid-19 is no longer the biggest issue facing hospitals. Staffing is.” Workforce issues dominated JPM this year and most presenters recognized these issues as their biggest focus and challenge. Dan and Keith discussed how health systems are thinking about staffing differently and how they're thinking about deploying technology differently to ease staffing demands and burnout. They also discussed some of the new challenges providers are facing as the market evolves – such as competition for new talent from virtual care companies, specialty providers, payers and many others – and new strategies for training, recruiting and retention a result.Top strategies for the future. With COVID becoming a normal part of operations, health systems are finally thinking about the future again with a clear eye towards strategy. In Dan's Fortune piece, “The greatest comeback in the history of health care,” he talked about the severe financial strains health systems faced over the past two years, with volumes down 30% to 40% in the early days of the pandemic. But now that the industry has weathered the storm and proven how critical and resilient it is, the focus is the future. From what Dan heard at JPM, he sees strategies falling into five critical areas that he and Keith discussed: M&A, investing in innovation, value-based care, creating destination centers, and deploying virtual care platforms.To hear Dan and Keith talk about these topics and more, listen to this episode of Healthcare is Hard: A Podcast for Insiders.

January 17, 2022: https://www.linkedin.com/in/logancm/ (Chris Logan), Senior Vice President and Chief Security Officer at https://www.censinet.com/ (Censinet) joins Bill for the news. Transcarent, a digital health platform for self-insured employers, closed a $200 million series C funding round with players like Northwell, Intermountain & Rush. Will telemedicine evolve to a dynamic and preferred experience or have we cut and pasted the traditional doctor's office experience into the computer screen and left it at that? Plus highlights from the JP Morgan Conference. Moderna's earnings were excellent. Sinovac went from slightly in the red in 2020 to 5.1 billion net income in 2021. Ascension is ready to take more risk when it comes to value-based payment models. And Intermountain Healthcare touted its acquisition-fueled shift away from fee-for-service care. Key Points: 00:00:00 - Intro 00:11:15 - Transcarent is going to change the experience employees have with their employer benefits 00:15:10 - We assume everybody understands how to navigate healthcare but they don't 00:21:30 - A health system should become a partner in health care as opposed to a partner in sick care 00:26:45 - How do we really transform what telemedicine looks like? https://www.censinet.com/ (Censinet) Stories: https://www.beckershospitalreview.com/innovation/northwell-intermountain-rush-invest-in-digital-health-platform-for-self-insured.html (Northwell, Intermountain & Rush invest in digital health platform for self-insured - Beckers Hospital Review) https://johnnosta.medium.com/the-urgent-need-for-telemedicine-2-0-dc4bd759a5f2 (The Urgent Need for Telemedicine 2.0 by John Nosta) https://www.modernhealthcare.com/finance/reporters-notebook-jp-morgans-2022-health-conference (Reporter's notebook: J.P. Morgan's 2022 health conference - Modern Healthcare) https://www.fiercehealthcare.com/hospitals/jpm22-day-1-medically-home-nabs-110m-from-baxter-mayo-clinic (JPM22, Day 1: JPMorgan partners with Vera Whole Health; Humana addresses lower MA enrollment outlook and more - Fierce Healthcare) https://www.natlawreview.com/article/day-one-notes-40th-annual-jp-morgan-healthcare-conference-2022 (Day One Notes for the 40th Annual J.P. Morgan Healthcare Conference, 2022 - The National Law Review)

There aren't many single events that bring together a Who's Who list of the leading private and public companies in biotech and synthetic biology. The JP Morgan Healthcare Conference is one of the rare exceptions. The annual event, held every January, is one of the biggest stages for companies to reveal innovative new products in development, announce acquisitions, and form landscape-shifting collaborations. Investors were left wanting more after the 2021 meeting, which was relatively subdued due to the coronavirus pandemic. The first few days of the 2022 event seemed to live up to historical expectations, with a handful of companies making splashy announcements so far. In this episode of the podcast, 7investing Lead Advisors Simon Erickson and Maxx Chatsko sit down to provide quick takeaways on some of the biggest reveals from the beginning of the 2022 JP Morgan Healthcare Conference. These include: The unveiling of a long-read DNA sequencing technology from Illumina (NASDAQ: ILMN) and an enzymatic DNA synthesis technology from Twist Bioscience (NASDAQ: TWST). Molecular testing leader Exact Sciences (NASDAQ: EXAS) used the stage to reveal that it comfortably beat full-year 2021 guidance and jump into hereditary cancer testing. Meanwhile, Beam Therapeutics (NASDAQ: BEAM) announced a research collaboration with Pfizer (NYSE: PFE) that had an unusual structure. Simon and Maxx also share their thoughts on the slow pace of merger and acquisitions (M&A) in drug development in the last two years — and why record cash balances and a constant need for innovation at the largest companies suggest that could change in 2022. Publicly-traded companies mentioned or alluded to in this podcast include Beam Therapeutics, CRISPR Therapeutics, Eli Lilly, Exact Sciences, Illumina, Intellia Therapeutics, Novo Nordisk, Pacific Biosciences, and Twist Bioscience. 7investing's advisors may own positions in the companies that are mentioned. Welcome to 7investing. We are here to empower you to invest in your future! We publish our 7 best ideas in the stock market to our subscribers for just $49 per month or $399 per year. Start your journey toward's financial independence: https://www.7investing.com/subscribe Stop by our website to level-up your investing education: https://www.7investing.com Follow us: ► https://www.facebook.com/7investing ► https://twitter.com/7investing ► https://instagram.com/7investing --- Send in a voice message: https://anchor.fm/7investing/message Support this podcast: https://anchor.fm/7investing/support

First, STAT health tech correspondent Katie Palmer joins us to recap the J.P. Morgan Healthcare Conference. Then, we discuss the latest twist in Biogen's quest to expand the use of Aduhelm and what it means for the treatment of Alzheimer's disease. Finally, Arrakis Therapeutics CEO Michael Gilman calls in to explain how targeting RNA can treat disease and why the characters in "Dune" don't just shoot each other with laser guns.

On day 2 we heard from Mayo, Northwell, Promedica, Prisma, City of Hope, Mass General Brigham, Indiana U, Jefferson Health, Bon Secours Mercy and Spectrum Health. Today we stay on high level themes.

The non-profit track. Sounds boring, but that is the sacrifice I make for my listeners. 9 hours in front of my computer to find the information that will benefit you. Today we touch on the themes from day 1.

FirstWord Pharma PLUS editors Michael Flanagan and Simon King discuss the biopharma news of their radars this week and look ahead to next week's JP Morgan Healthcare conference, which due to the pandemic will take place virtually for the second year in a row.

First, emergency room physician Craig Spencer joins us to talk about how the Omicron variant is impacting New York City and what the coming months have in store. Then, we look ahead to the New Year in biotech with a preview of the J.P. Morgan Healthcare Conference. We start with a look at the latest news in the life sciences, including Elizabeth Holmes' guilty verdict and the ongoing Aduhelm saga.

We've come to our last episode of the year, and first, STAT's Helen Branswell joins us to talk about Omicron, boosters, and the past and future of the Covid-19 pandemic. Then, we'll review the year that was in biotech, discuss the suddenly virtual J.P. Morgan Healthcare Conference, and look forward to 2022.

We thought it would be interesting to have a discussion with three biopharmaceutical executives about how they are preparing for this unique 2021 JPM and how those preparations are different than what they've done in the past.

Publicis Health CEO Alexandra Von Plato debriefs with Marc Iskowitz, MM+M's editor-at-large, about a J.P. Morgan Healthcare Conference like no other.

We're devoting this episode to the news coming out of the just-concluded J.P. Morgan Healthcare Conference, the drug industry's largest annual meeting. First, we'll dissect Eli Lilly's surprising data on a new Alzheimer's disease treatment and dig into its implications for the field. Then, we discuss whether there's a bubble inflating in the genome editing world, debate who will run the FDA under a President Biden, and consider the legacy of Moncef Slaoui, the outgoing leader of Operation Warp Speed.

Trevor and Steve chat with Nancy Ham, CEO of WebPT, during the 2020 J.P. Morgan Healthcare Conference.

As patients, the traditional pharmacy business seems to be a mess. It appears to be a jumble of information exchange, insurance contracts, middlemen, generics, phone calls, faxes, cross-subsidies, and misaligned incentives. The process can be frustrating, time-consuming, and expensive. As if that's not bad enough, it can often result in patients not adhering to their medication routine. Fortunately, there are some creative entrepreneurs working on ways to improve the system. Leading the charge is Alto Pharmacy. While in the Bay Area for the recent J.P. Morgan Healthcare Conference, Niko Skievaski sat down with Alto's CEO Mattieu Gamache-Asselin for a lively discussion about the pharmacy of the future. We invite you to enjoy the entire conversation. A few highlights can be found at these times: 02:08 – Matt's back-end roots working with Parse 06:10 – Buying a pharmacy to really understand both the business and patient needs. 11:10 – Creating the ideal patient experience 20:21 – Alto's process and how patients realize value 26:43 – New challenges to be solved in the months and years ahead 31:39 – With all the stakeholders in healthcare, is it possible to create value for everyone? 37:11 – Create change “one step at a time” While Alto is relatively unknown to consumers nationwide today, that's only because they've prudently chosen a disciplined approach to perfecting their new model for pharmacy service. Focusing on select markets allows Alto to prove the economics of their model, discover the most efficient way to operate, and, most importantly, ensure great customer experiences. This strategy will serve them well in the long term and it's only a matter of time before Alto is a well-known national brand name. Thank you for listening to this episode of The Redox Podcast.

As the year draws to a close, we continue what's become an annual tradition and look back on the year in biotech and ahead to the J.P. Morgan Healthcare Conference and beyond with Adam Feuerstein, senior biotech writer for STAT News. Adam tries to make sense of a puzzling year for biotech that seemed full of contradictions, offers some thoughts on the highs and lows of the past 12 months, and discusses what he'll be watching for during the J.P. Morgan Healthcare Conference.

In the inaugural “A Healthy Dose” podcast, Trevor and Steve get Ambar Bhattacharyya, Manager Director at Maverick Ventures, Sean Duffy, CEO of Omada Health, and Chrissy Farr, healthcare and technology journalist at Fast Company, together for a roundtable discussion to recap the 2017 JP Morgan Healthcare Conference. The group reflects on the climate of healthcare following the presidential election and the investment trends.